Antares pharma announces positive results from phase i study for atrs-1902 for adrenal crisis rescue

Ewing, n.j., jan. 11, 2022 (globe newswire) -- antares pharma, inc. (nasdaq: atrs) (the “company”), a specialty pharmaceutical company, today announced positive results from a phase i study for atrs-1902 for adrenal crisis. the positive results support the advancement of the atrs-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our vai™ novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.
ATRS Ratings Summary
ATRS Quant Ranking